Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics (PBLA)
OTHER OTC:PBLA
RESEARCH TOOLSreports
Total Valuation
Panbela Therapeutics has a market cap or net worth of $1.15M. The enterprise value is $7.98M.
Market Cap$1.15M
Enterprise Value$7.98M
Share Statistics
Panbela Therapeutics has 4,854,831 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,854,831
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Panbela Therapeutics’s return on equity (ROE) is 5.36 and return on invested capital (ROIC) is -10520.48%.
Return on Equity (ROE)5.36
Return on Assets (ROA)-2.14
Return on Invested Capital (ROIC)-10520.48%
Return on Capital Employed (ROCE)99.41
Revenue Per Employee0.00
Profits Per Employee-3.61M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Panbela Therapeutics is >-0.01. Panbela Therapeutics’s PEG ratio is >-0.01.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value>-0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, Panbela Therapeutics had revenue of 0.00 and earned -25.26M in profits. Earnings per share was -232.43K.
Revenue0.00
Gross Profit-25.65M
Operating Income-51.29M
Pretax Income-25.45M
Net Income-25.26M
EBITDA-51.29M
Earnings Per Share (EPS)-232.43K
Cash Flow
In the last 12 months, operating cash flow was -15.57M and capital expenditures 0.00, giving a free cash flow of -15.57M billion.
Operating Cash Flow-15.57M
Free Cash Flow-15.57M
Free Cash Flow per Share-3.21
Dividends & Yields
Panbela Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.27
52-Week Price Change-15.79%
50-Day Moving Average0.33
200-Day Moving Average0.35
Relative Strength Index (RSI)53.37
Average Volume (3m)17.78K
Important Dates
Panbela Therapeutics upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Panbela Therapeutics as a current ratio of 0.25, with Debt / Equity ratio of -35.19%
Current Ratio0.25
Quick Ratio0.25
Debt to Market Cap2.61K
Net Debt to EBITDA-0.05
Interest Coverage Ratio161.81
Taxes
In the past 12 months, Panbela Therapeutics has paid -186.00K in taxes.
Income Tax-186.00K
Effective Tax Rate<0.01
Enterprise Valuation
Panbela Therapeutics EV to EBITDA ratio is -0.05, with an EV/FCF ratio of -0.10.
EV to Sales0.00
EV to EBITDA-0.05
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
Panbela Therapeutics has $142.00K in cash and marketable securities with $350.00K in debt, giving a net cash position of $6.25M billion.
Cash & Marketable Securities$142.00K
Total Debt$350.00K
Net Cash$6.25M
Net Cash Per Share$1.29
Tangible Book Value Per Share-$43.33K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Panbela Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast99.19%